← Back to all trials
Recruiting
NCT06824454
Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients
Conditions: Hypophosphatemia, Kidney Transplantation
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 90
Sponsor: Stanford University
Location: Stanford University Stanford California
Summary
The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.
Eligibility Criteria
Inclusion Criteria:
* Adult kidney transplant patients.
* No known contraindications to Dipyridamole
Exclusion Criteria:
* Contraindications to Dipyridamole.
* Patients with delayed graft function (defined as the need for dialysis within seven days post-transplantation).
* Patients requiring Plavix, direct oral anticoagulants (DOACs), or Coumadin.
Source: ClinicalTrials.gov (NCT06824454). StuddyBuddy aggregates publicly available trial information.
